Get the Stockscreener App
8.18
7.47%
-0.66
Akari Therapeutics Plc Adr Stock (AKTX) Forecast
The Akari Therapeutics Plc Adr (AKTX) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $40.00, representing a +389.00% increase from the current price of $8.18. The highest analyst price target is $41.29, and the lowest is $38.71.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month AKTX Price Target
Average 227.98
(+2,687% Upside)
Is Akari Therapeutics Plc Adr (AKTX) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 44.27 | Neutral |
| STOCH(9,6) | 31.64 | Neutral |
| STOCHRSI(14) | 67.08 | Neutral |
| MACD(12,26) | -0.4114 | Sell |
| ADX(14) | 16.52 | Neutral |
| William %R | -68.51 | Neutral |
| CCI(14) | -30.10 | Neutral |
Buy: 0
Sell: 1
Neutral: 6
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
8.3595
Sell
|
8.4264
Sell
|
| MA20 |
8.9445
Sell
|
8.7888
Sell
|
| MA50 |
9.0679
Sell
|
9.2065
Sell
|
| MA100 |
10.47
Sell
|
9.6533
Sell
|
| MA200 |
9.198
Sell
|
13.37
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, AKTX could be considered a Strong Sell, with 17 technical analysis indicators signaling 0 Buy signals, 11 signaling Sell signals and 6 Neutral signals. This might not be a good time to consider opening new positions on AKTX, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 44.27 indicates that AKTX is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 31.64 indicates that AKTX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 67.08 indicates that AKTX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 16.52 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -30.1 indicates that AKTX is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term AKTX price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Akari Therapeutics Plc Adr financial reports and earnings history, Akari Therapeutics Plc Adr (AKTX) stock could reach $427.34 by 2030, $2,565.86 by 2040 and $5,101.09 by 2050. See the projected annual prices until 2050 of the Akari Therapeutics Plc Adr stock below:
- Akari Therapeutics Plc Adr (AKTX) is expected to reach an average price of $1,359.60 in 2035, with a high prediction of $1,371.98 and a low estimate of $1,365.60. This indicates an $16,521% rise from the last recorded price of $8.18.
- Akari Therapeutics Plc Adr (AKTX) stock is projected to chart a bullish course in 2040, with an average price target of $2,508.80, representing an $30,570% surge from its current level. The forecast ranges from a conservative $2,515.20 to a sky-high $2,565.86.
- Our analysts predict Akari Therapeutics Plc Adr (AKTX) to jump 46,244% by 2045, soaring from $3,768.35 to an average price of $3,790.93, potentially reaching $3,742.25. While $3,768.35 is the low estimate, the potential upside is significant.
- Akari Therapeutics Plc Adr (AKTX) stock is expected to climb by 2050, reaching an average of $5,010.00, a $61,147% jump from its current level. However, a wide range of estimates exists, with high and low targets of $5,101.09 and $5,114.00, respectively, highlighting the market's uncertainty.
Akari Therapeutics Plc Adr Stock (AKTX) Year by Year Forecast
Akari Therapeutics Plc Adr Stock (AKTX) Price Forecast for 2026
The predicted value for Akari Therapeutics Plc Adr (AKTX) in 2026 is set at an average of $57.36. Estimates vary from a peak of $111.70 to a trough of $3.015, indicating an +601.19% surge from the present price of $8.18.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| November, 2026 | $20.49 | $38.71 | $41.29 | +150.50% |
| December, 2026 | $74.27 | $98.27 | $46.83 | +807.96% |
Akari Therapeutics Plc Adr Stock (AKTX) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Akari Therapeutics Plc Adr (AKTX) is $363.62, with a high forecast of $690.05 and a low forecast of $37.19. This indicates an +4,345% increase from the last price of $8.18.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $144.05 | $152.05 | $100.61 | +1,661% |
| February, 2027 | $101.83 | $214.94 | $170.39 | +1,145% |
| March, 2027 | $315.06 | $200.17 | $159.45 | +3,752% |
| April, 2027 | $284.84 | $300.84 | $306.50 | +3,382% |
| May, 2027 | $302.06 | $311.17 | $264.28 | +3,593% |
| June, 2027 | $251.84 | $275.84 | $244.95 | +2,979% |
| July, 2027 | $377.62 | $299.29 | $345.62 | +4,516% |
| August, 2027 | $418.77 | $432.52 | $418.77 | +5,019% |
| September, 2027 | $48.63 | $37.19 | $182.30 | +494.51% |
| October, 2027 | $278.41 | $191.52 | $158.41 | +3,304% |
| November, 2027 | $698.52 | $585.86 | $599.64 | +8,439% |
| December, 2027 | $679.02 | $712.77 | $690.05 | +8,201% |
Akari Therapeutics Plc Adr Stock (AKTX) Price Forecast for 2028
In 2028, Akari Therapeutics Plc Adr (AKTX) is projected to reach an average price of $702.22, with a high projection of $776.93 and a low estimate of $627.51. This indicates an +8,485% rise from the last price of $8.18.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $615.68 | $627.51 | $602.32 | +7,427% |
| February, 2028 | $652.50 | $642.09 | $628.42 | +7,877% |
| March, 2028 | $610.20 | $646.76 | $599.87 | +7,360% |
| April, 2028 | $663.90 | $633.27 | $598.13 | +8,016% |
| May, 2028 | $760.17 | $714.79 | $709.21 | +9,193% |
| June, 2028 | $790.91 | $788.66 | $774.99 | +9,569% |
| July, 2028 | $761.98 | $784.22 | $776.93 | +9,215% |
| August, 2028 | $785.60 | $783.11 | $763.91 | +9,504% |
| September, 2028 | $748.66 | $763.78 | $769.44 | +9,052% |
| October, 2028 | $656.84 | $700.60 | $739.22 | +7,930% |
| November, 2028 | $724.78 | $672.85 | $706.38 | +8,760% |
| December, 2028 | $687.76 | $700.16 | $707.43 | +8,308% |
Akari Therapeutics Plc Adr Stock (AKTX) Price Forecast for 2029
The 2029 price forecast for Akari Therapeutics Plc Adr Stock (AKTX) is $563.30 on average, with a high prediction of $666.34 and a low estimate of $460.27. This represents an +6,786% increase from the previous price of $8.18.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $665.79 | $680.79 | $666.34 | +8,039% |
| February, 2029 | $663.57 | $663.43 | $657.23 | +8,012% |
| March, 2029 | $648.55 | $652.95 | $650.46 | +7,828% |
| April, 2029 | $635.38 | $637.38 | $640.80 | +7,667% |
| May, 2029 | $632.76 | $634.76 | $630.51 | +7,635% |
| June, 2029 | $620.14 | $628.14 | $627.25 | +7,481% |
| July, 2029 | $616.76 | $620.63 | $615.99 | +7,440% |
| August, 2029 | $625.74 | $627.94 | $626.90 | +7,550% |
| September, 2029 | $594.12 | $598.52 | $601.79 | +7,163% |
| October, 2029 | $483.75 | $524.15 | $567.81 | +5,814% |
| November, 2029 | $472.73 | $473.93 | $477.84 | +5,679% |
| December, 2029 | $454.56 | $460.27 | $449.96 | +5,457% |
Akari Therapeutics Plc Adr Stock (AKTX) Price Forecast for 2030
Akari Therapeutics Plc Adr Stock (AKTX) is expected to reach an average price of $385.74 in 2030, with a high forecast of $461.17 and a low forecast of $310.30. This signifies an +4,616% surge from the last price of $8.18.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $442.74 | $440.91 | $427.34 | +5,312% |
| February, 2030 | $434.49 | $442.87 | $439.27 | +5,212% |
| March, 2030 | $440.50 | $444.50 | $441.05 | +5,285% |
| April, 2030 | $465.32 | $434.74 | $461.17 | +5,589% |
| May, 2030 | $456.77 | $457.90 | $454.86 | +5,484% |
| June, 2030 | $429.72 | $432.06 | $440.55 | +5,153% |
| July, 2030 | $415.71 | $416.51 | $420.33 | +4,982% |
| August, 2030 | $375.09 | $395.49 | $405.55 | +4,485% |
| September, 2030 | $365.31 | $369.82 | $376.38 | +4,366% |
| October, 2030 | $344.89 | $344.89 | $345.76 | +4,116% |
| November, 2030 | $327.80 | $328.22 | $333.94 | +3,907% |
| December, 2030 | $307.50 | $310.30 | $320.52 | +3,659% |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):